AbCellera Biologics' (ABCL) "Overweight" Rating Reaffirmed at Piper Jaffray Companies
AbCellera Biologics (NASDAQ:ABCL – Get Free Report)‘s stock had its “overweight” rating reissued by equities researchers at Piper Jaffray Companies in a report issued on Friday, Stock Target Advisor reports. They currently have a $20.00 price objective on the stock. Piper Jaffray Companies’ price target would suggest a potential upside of 402.51% from the company’s […]